Edition:
United States

Endologix Inc (ELGX.OQ)

ELGX.OQ on NASDAQ Stock Exchange Global Select Market

5.10USD
27 Jun 2017
Change (% chg)

-- (--)
Prev Close
$5.10
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
356,941
52-wk High
$14.49
52-wk Low
$4.20

ELGX.OQ

Chart for ELGX.OQ

About

Endologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company's products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular... (more)

Overall

Beta: 0.65
Market Cap(Mil.): $423.17
Shares Outstanding(Mil.): 82.98
Dividend: --
Yield (%): --

Financials

  ELGX.OQ Industry Sector
P/E (TTM): -- 34.12 19.11
EPS (TTM): -1.56 -- --
ROI: -39.61 13.11 -5.00
ROE: -111.52 15.62 -4.24

BRIEF-Partner Fund Management reports 6.4 pct passive stake in Endologix ‍​

* Partner fund management, l.p. Reports 6.4 percent passive stake in endologix inc as of may 22, 2017 - sec filing‍​ Source text - http://bit.ly/2qGuWLN Further company coverage:

Jun 01 2017

BRIEF-Endologix provides an update on the Nellix EVAS System

* Endologix provides an update on the Nellix Endovascular Aneurysm Sealing System U.S. regulatory status

May 17 2017

BRIEF-Endologix reports Q1 loss per share $0.26

* Q1 earnings per share view $-0.21 -- Thomson Reuters I/B/E/S

May 04 2017

BRIEF-Endologix enters into $170 mln credit facility with Deerfield Management

* Endologix enters into $170 million credit facility with Deerfield Management

Apr 04 2017

BRIEF-Endologix enrollS first patients in ELEVATE IDE clinical study

* Endologix Inc announces enrollment of first patients in elevate IDE clinical study

Mar 31 2017

BRIEF-Brown Capital reports a 10.58 pct passive stake in Endologix Inc

* Brown Capital Management LLC reports a 10.58 percent passive stake in Endologix Inc as of Feb 28, 2017 Source text:(http://bit.ly/2miclCd) Further company coverage:

Mar 07 2017

BRIEF-Endologix reports Q4 loss per share of $0.30

* Endologix reports results for the fourth quarter and full year 2016

Feb 22 2017

BRIEF-Endologix completes patient enrollment in the Ovation LUCY Study

* Endologix completes patient enrollment in the Ovation LUCY Study Source text for Eikon: Further company coverage:

Feb 14 2017

BRIEF-COLUMBIA WANGER ASSET MANAGEMENT REPORTS 7.6 PCT PASSIVE STAKE IN ENDOLOGIX INC AS OF DEC 31, 2016

* COLUMBIA WANGER ASSET MANAGEMENT LLC REPORTS 7.6 PERCENT PASSIVE STAKE IN ENDOLOGIX INC AS OF DEC 31, 2016 - SEC FILING Source text (http://bit.ly/2kcBtG5) Further company coverage:

Feb 10 2017

BRIEF-Endologix appoints Dan Lemaitre as chairman of board

* Endologix announces appointment of Dan Lemaitre as chairman of the board

Feb 06 2017

More From Around the Web

Competitors

Earnings vs. Estimates